A Phase 3 interventional study of nivolumab and ipilimumab in Carcinoma, Renal Cell, sponsored by Bristol-Myers Squibb. Completed at 200 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.
Among the 63 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 2nd largest by enrollment, is one of 13 that started in 2017, is one of 8 in phase 3, and was the 30th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →9 of the 63 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 70+
Mayo Clinic · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 39 · Phase 3 8 · Phase 4 4
First in 2006; this study’s year is marked. 13 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,641 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 54 across the 63 interventional studies. Of the 34 that completed or were terminated, 19 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb: 5 open now, 8 under way, 2 of them phase 3. Of 32 finished, 16 (50%) have results posted.
Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one has the largest enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2017, is one of 6 in phase 3, and was the 22nd registered.
Bristol-Myers Squibb’s Carcinoma, Renal Cell studies by the year they started, since 2003.
9 of the studies testing nivolumab in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04413123Bradley A. McGregor, MDCabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | 2026-12-20 |
| NCT02210117M.D. Anderson Cancer CenterNivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | 2026-12-31 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT04322955Mark SteinCYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | 2027-05 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 63 studies testing nivolumab in Carcinoma, Renal Cell, from their registry updates:
Among Bristol-Myers Squibb’s 42 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.
The study has two primary endpoints. The first primary completion date is anticipated to be reached July 2022 (DFS in Part A). The second primary completion date is anticipated to be reached July 2024 (DFS in Part B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: nivolumab · Biological: ipilimumab
Drug: nivolumab placebo · Drug: ipilimumab placebo
Biological: nivolumab · Biological: ipilimumab
Drug: nivolumab placebo · Drug: ipilimumab placebo
Biological: nivolumab · Drug: ipilimumab placebo
Specified dose on specified days
Also known as: Opdivo
Specified dose on specified days
Also known as: Yervoy
Specified dose on specified days
Specified dose on specified days
Disease-Free Survival (DFS) by BICR - Treatment Part A and B
Disease-Free Survival (DFS) is defined as the time from randomization to development of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary renal cell carcinoma (RCC) primary cancer), distance metastasis, or death, whichever came first per Blinded Independent Central Review (BICR) based on Kaplan-Meier estimates.
Time frame: From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)
Overall Survival (OS) - Treatment Part A and B
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the participants was known to be alive. Based on Kaplan-Meier estimates.
Time frame: From randomization to the date of death (up to approximately 72 months)
Overall Survival (OS) Rate (5 Years) - Treatment Part A and B
Overall survival rate at 5 years is defined as the percentage of participants who are alive at 5 years.
Time frame: At 5 years
Disease-Free Survival (DFS) Per BICR in Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B
Disease-Free Survival (DFS) is defined as the time from randomization to development of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary renal cell carcinoma (RCC) primary cancer), distance metastasis, or death, whichever came first per Blinded Independent Central Review (BICR) based on Kaplan-Meier estimates.
Time frame: From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)
Overall Survival (OS) in the Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the participants was known to be alive. Based on Kaplan-Meier estimates
Time frame: From randomization to the date of death (up to approximately 72 months)
The Number of Participants With Adverse Events up to 30 Days After Last Dose of Study Therapy - Treatment Part A
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
Time frame: From first dose to 30 days post last dose (up to approximately 40 weeks)
The Number of Participants With Adverse Events up to 30 Days After Last Dose of Study Therapy - Treatment Part B
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
Time frame: From first dose to 30 days post last dose (up to approximately 40 weeks)
The Number of Participants With Adverse Events up to 100 Days After Last Dose of Study Therapy - Treatment Part A
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
Time frame: From first dose to 100 days post last dose (up to approximately 50 weeks)
The Number of Participants With Adverse Events up to 100 Days After Last Dose of Study Therapy - Treatment Part B
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
Time frame: From first dose to 100 days post last dose (up to approximately 50 weeks)
The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 30 Days - Treatment Part A
Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.
Time frame: From first dose to 30 days post last dose (up to approximately 40 weeks)
The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 30 Days - Treatment Part B
Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.
Time frame: From first dose to 30 days post last dose (up to approximately 40 weeks)
The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 100 Days - Treatment Part A
Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.
Time frame: From first dose to 100 days post last dose (up to approximately 50 weeks)
The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 100 Days - Treatment Part B
Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.
Time frame: From first dose to 100 days post last dose (up to approximately 50 weeks)
| Milestone | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|---|---|
| Started | 405 | 411 | 206 | 208 | 411 |
| Completed | 404 | 407 | 204 | 207 | 408 |
| Not completed | 1 | 4 | 2 | 1 | 3 |
| Withdrew: Participants withdrew consent | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Participant no longer meets study criteria | 0 | 3 | 1 | 1 | 3 |
| Withdrew: Other reasons | 1 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|---|---|
| Started | 404 | 407 | 0 | 0 | 0 |
| Completed | 229 | 360 | 0 | 0 | 0 |
| Not completed | 175 | 47 | 0 | 0 | 0 |
| Withdrew: Disease recurrence | 10 | 20 | 0 | 0 | 0 |
| Withdrew: Study drug toxicity | 132 | 5 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event unrelated to study drug | 9 | 4 | 0 | 0 | 0 |
| Withdrew: Participant request to discontinue treatment | 9 | 4 | 0 | 0 | 0 |
| Withdrew: Participant withdrew consent | 2 | 4 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Poor/non-compliance | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other reasons | 11 | 8 | 0 | 0 | 0 |
| Milestone | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|---|---|
| Started | 0 | 0 | 204 | 207 | 408 |
| Completed | 0 | 0 | 118 | 182 | 327 |
| Not completed | 0 | 0 | 86 | 25 | 81 |
| Withdrew: Disease recurrence | 0 | 0 | 6 | 12 | 10 |
| Withdrew: Study drug toxicity | 0 | 0 | 63 | 3 | 45 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event unrelated to study drug | 0 | 0 | 5 | 2 | 12 |
| Withdrew: Participants request to discontinue study treatment | 0 | 0 | 6 | 4 | 6 |
| Withdrew: Participant withdrew consent | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Poor/non-compliance | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Other reasons | 0 | 0 | 3 | 1 | 5 |
Disease-Free Survival (DFS) is defined as the time from randomization to development of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary renal cell carcinoma (RCC) primary cancer), distance metastasis, or death, whichever came first per Blinded Independent Central Review (BICR) based on Kaplan-Meier estimates.
| Months | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|---|---|
| Disease-Free Survival (DFS) by BICR - Treatment Part A and B | NA (NA to NA) | NA (65.58 to NA) | — | NA (NA to NA) | NA (NA to NA) |
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the participants was known to be alive. Based on Kaplan-Meier estimates.
| Months | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|---|---|
| Overall Survival (OS) - Treatment Part A and B | NA (NA to NA) | NA (NA to NA) | — | NA (NA to NA) | NA (NA to NA) |
Overall survival rate at 5 years is defined as the percentage of participants who are alive at 5 years.
| Percent of participants | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|---|---|
| Overall Survival (OS) Rate (5 Years) - Treatment Part A and B | 85.0 (80.8 to 88.3) | 87.2 (82.8 to 90.5) | — | — | — |
Disease-Free Survival (DFS) is defined as the time from randomization to development of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary renal cell carcinoma (RCC) primary cancer), distance metastasis, or death, whichever came first per Blinded Independent Central Review (BICR) based on Kaplan-Meier estimates.
| Months | Treatment Part B: Nivo + Ipi | Treatment Part B: Nivo |
|---|---|---|
| Disease-Free Survival (DFS) Per BICR in Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B | NA (36.17 to NA) | NA (NA to NA) |
Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the participants was known to be alive. Based on Kaplan-Meier estimates
| Months | Treatment Part B: Nivo + Ipi | Treatment Part B: Nivo |
|---|---|---|
| Overall Survival (OS) in the Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B | NA (NA to NA) | NA (NA to NA) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
| Participants | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo |
|---|---|---|
| Any Grade AE | 392 | 362 |
| Grade 3-4 AE | 154 | 44 |
| Grade 5 AE | 1 | 0 |
| Any Grade Drug-Related AE | 359 | 230 |
| Grade 3-4 Drug-Related AE | 114 | 8 |
| Grade 5 Drug-Related AE | 0 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
| Participants | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|
| Any Grade AE | 193 | 182 | 362 |
| Grade 3-4 AE | 59 | 31 | 70 |
| Grade 5 AE | 1 | 1 | 0 |
| Any Grade Drug-Related AE | 173 | 107 | 297 |
| Grade 3-4 Drug-Related AE | 41 | 4 | 36 |
| Grade 5 Drug-Related AE | 0 | 0 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
| Participants | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo |
|---|---|---|
| Any Grade AE | 393 | 365 |
| Grade 3-4 AE | 167 | 52 |
| Grade 5 AE | 4 | 1 |
| Any Grade Drug-Related AE | 361 | 230 |
| Grade 3-4 Drug-Related AE | 128 | 9 |
| Grade 5 Drug-Related AE | 2 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.
| Participants | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|
| Any Grade AE | 196 | 182 | 367 |
| Grade 3-4 AE | 68 | 32 | 85 |
| Grade 5 AE | 5 | 2 | 2 |
| Any Grade Drug-Related AE | 175 | 108 | 300 |
| Grade 3-4 Drug-Related AE | 46 | 5 | 46 |
| Grade 5 Drug-Related AE | 0 | 0 | 0 |
Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.
| Participants | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo |
|---|---|---|
| HEMOGLOBIN | 1 | 1 |
| PLATELET COUNT | 1 | 0 |
| LEUKOCYTES, LOCAL LAB | 0 | 0 |
| LYMPHOCYTES (ABSOLUTE), TOTAL | 6 | 3 |
| ABSOLUTE NEUTROPHIL COUNT | 2 | 0 |
| ALKALINE PHOSPHATASE, LOCAL LAB | 3 | 0 |
| ASPARTATE AMINOTRANSFERASE, LOCAL LAB | 14 | 3 |
| ALANINE AMINOTRANSFERASE, LOCAL LAB | 16 | 5 |
| BILIRUBIN, TOTAL, LOCAL LAB | 1 | 0 |
| CREATININE, LOCAL LAB | 1 | 1 |
| HYPERNATREMIA | 0 | 0 |
| HYPONATREMIA | 28 | 7 |
| HYPERKALEMIA | 6 | 5 |
| HYPOKALEMIA | 3 | 1 |
| HYPERCALCEMIA | 3 | 0 |
| HYPOCALCEMIA | 1 | 0 |
| HYPERMAGNESEMIA | 1 | 1 |
| HYPOMAGNESEMIA | 1 | 0 |
| HYPERGLYCEMIA | 6 | 1 |
| HYPOGLYCEMIA | 1 | 0 |
Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.
| Participants | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|
| HEMOGLOBIN | 0 | 3 | 0 |
| PLATELET COUNT | 0 | 1 | 0 |
| LEUKOCYTES, LOCAL LAB | 0 | 0 | 1 |
| LYMPHOCYTES (ABSOLUTE), TOTAL | 3 | 1 | 4 |
| ABSOLUTE NEUTROPHIL COUNT | 0 | 0 | 1 |
| ALKALINE PHOSPHATASE, LOCAL LAB | 1 | 1 | 0 |
| ASPARTATE AMINOTRANSFERASE, LOCAL LAB | 4 | 4 | 5 |
| ALANINE AMINOTRANSFERASE, LOCAL LAB | 7 | 3 | 8 |
| BILIRUBIN, TOTAL, LOCAL LAB | 0 | 1 | 0 |
| CREATININE, LOCAL LAB | 3 | 0 | 0 |
| HYPERNATREMIA | 0 | 0 | 0 |
| HYPONATREMIA | 11 | 1 | 9 |
| HYPERKALEMIA | 1 | 2 | 2 |
| HYPOKALEMIA | 1 | 1 | 0 |
| HYPERCALCEMIA | 1 | 0 | 1 |
| HYPOCALCEMIA | 0 | 1 | 0 |
| HYPERMAGNESEMIA | 2 | 2 | 3 |
| HYPOMAGNESEMIA | 0 | 1 | 1 |
| HYPERGLYCEMIA | 3 | 1 | 3 |
| HYPOGLYCEMIA | 0 | 0 | 1 |
Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.
| Participants | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo |
|---|---|---|
| HEMOGLOBIN | 1 | 1 |
| PLATELET COUNT | 1 | 0 |
| LEUKOCYTES, LOCAL LAB | 0 | 0 |
| LYMPHOCYTES (ABSOLUTE), TOTAL | 11 | 3 |
| ABSOLUTE NEUTROPHIL COUNT | 2 | 0 |
| ALKALINE PHOSPHATASE, LOCAL LAB | 5 | 0 |
| ASPARTATE AMINOTRANSFERASE, LOCAL LAB | 17 | 3 |
| ALANINE AMINOTRANSFERASE, LOCAL LAB | 20 | 6 |
| BILIRUBIN, TOTAL, LOCAL LAB | 3 | 0 |
| CREATININE, LOCAL LAB | 4 | 1 |
| HYPERNATREMIA | 0 | 0 |
| HYPONATREMIA | 30 | 7 |
| HYPERKALEMIA | 6 | 5 |
| HYPOKALEMIA | 5 | 1 |
| HYPERCALCEMIA | 3 | 0 |
| HYPOCALCEMIA | 1 | 0 |
| HYPERMAGNESEMIA | 1 | 1 |
| HYPOMAGNESEMIA | 1 | 0 |
| HYPERGLYCEMIA | 7 | 1 |
| HYPOGLYCEMIA | 1 | 0 |
Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.
| Participants | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|
| HEMOGLOBIN | 2 | 3 | 1 |
| PLATELET COUNT | 0 | 1 | 0 |
| LEUKOCYTES, LOCAL LAB | 0 | 0 | 2 |
| LYMPHOCYTES (ABSOLUTE), TOTAL | 3 | 2 | 7 |
| ABSOLUTE NEUTROPHIL COUNT | 0 | 0 | 2 |
| ALKALINE PHOSPHATASE, LOCAL LAB | 2 | 1 | 0 |
| ASPARTATE AMINOTRANSFERASE, LOCAL LAB | 6 | 4 | 6 |
| ALANINE AMINOTRANSFERASE, LOCAL LAB | 9 | 3 | 10 |
| BILIRUBIN, TOTAL, LOCAL LAB | 0 | 1 | 0 |
| CREATININE, LOCAL LAB | 4 | 0 | 3 |
| HYPERNATREMIA | 0 | 0 | 0 |
| HYPONATREMIA | 12 | 1 | 13 |
| HYPERKALEMIA | 1 | 2 | 4 |
| HYPOKALEMIA | 1 | 2 | 2 |
| HYPERCALCEMIA | 1 | 0 | 1 |
| HYPOCALCEMIA | 0 | 1 | 1 |
| HYPERMAGNESEMIA | 3 | 2 | 3 |
| HYPOMAGNESEMIA | 0 | 1 | 1 |
| HYPERGLYCEMIA | 3 | 1 | 4 |
| HYPOGLYCEMIA | 0 | 0 | 1 |
Collected over All-cause mortality was assessed from a participants first dose to their study completion (up to approximately 72 months) SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 50 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Part A and B: Nivo + Ipi | 65/611 (10.6%) | 196/608 (32.2%) | 544/608 (89.5%) |
| Treatment Part A and B: Placebo | 55/619 (8.9%) | 49/614 (8%) | 469/614 (76.4%) |
| Treatment Part B: Nivo | 22/411 (5.4%) | 56/408 (13.7%) | 325/408 (79.7%) |
| Event | Treatment Part A and B: Nivo + Ipi | Treatment Part A and B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|
| Adrenal insufficiencyEndocrine disorders | 21/608 | 0/614 | 3/408 |
| DiarrhoeaGastrointestinal disorders | 16/608 | 1/614 | 0/408 |
| Acute kidney injuryRenal and urinary disorders | 13/608 | 1/614 | 2/408 |
| HypophysitisEndocrine disorders | 12/608 | 0/614 | 0/408 |
| ColitisGastrointestinal disorders | 12/608 | 0/614 | 1/408 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 7/608 | 1/614 | 4/408 |
| Immune-mediated enterocolitisGastrointestinal disorders | 6/608 | 0/614 | 0/408 |
| PneumoniaInfections and infestations | 6/608 | 1/614 | 1/408 |
| HyponatraemiaMetabolism and nutrition disorders | 6/608 | 0/614 | 2/408 |
| VomitingGastrointestinal disorders | 5/608 | 0/614 | 0/408 |
| Event | Treatment Part A and B: Nivo + Ipi | Treatment Part A and B: Placebo | Treatment Part B: Nivo |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 213/608 | 103/614 | 103/408 |
| FatigueGeneral disorders | 189/608 | 158/614 | 99/408 |
| DiarrhoeaGastrointestinal disorders | 180/608 | 120/614 | 77/408 |
| HypothyroidismEndocrine disorders | 131/608 | 28/614 | 54/408 |
| RashSkin and subcutaneous tissue disorders | 131/608 | 57/614 | 50/408 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 111/608 | 97/614 | 58/408 |
| NauseaGastrointestinal disorders | 102/608 | 73/614 | 53/408 |
| HeadacheNervous system disorders | 102/608 | 89/614 | 53/408 |
| HyperthyroidismEndocrine disorders | 98/608 | 8/614 | 47/408 |
| Blood creatinine increasedInvestigations | 82/608 | 59/614 | 40/408 |
| Age, Customized(Participants) | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo | Total |
|---|---|---|---|---|---|---|
| < 65 | 293 | 301 | 132 | 137 | 279 | 1142 |
| >= 65 AND < 75 | 93 | 91 | 64 | 60 | 108 | 416 |
| >= 75 AND < 85 | 19 | 19 | 10 | 11 | 23 | 82 |
| >= 85 | 0 | 0 | 0 | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo | Total |
|---|---|---|---|---|---|---|
| Female | 119 | 117 | 59 | 67 | 106 | 468 |
| Male | 286 | 294 | 147 | 141 | 305 | 1173 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 41 | 44 | 26 | 34 | 67 | 212 |
| Not Hispanic or Latino | 189 | 197 | 93 | 79 | 157 | 715 |
| Unknown or Not Reported | 175 | 170 | 87 | 95 | 187 | 714 |
| Race (NIH/OMB)(Participants) | Treatment Part A: Nivo + Ipi | Treatment Part A: Placebo | Treatment Part B: Nivo + Ipi | Treatment Part B: Placebo | Treatment Part B: Nivo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 5 | 3 | 14 | 25 |
| Asian | 93 | 65 | 20 | 26 | 50 | 254 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 3 | 6 | 0 | 1 | 4 | 14 |
| White | 303 | 322 | 173 | 169 | 331 | 1298 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 14 | 8 | 9 | 12 | 49 |
Showing the first 100 of 200 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Sep 2023, 74 months.
Results were first posted in Dec 2024, 1 year 2 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 74 months is above that.
Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab